Describing mode of death in three major cardiac amyloidosis subtypes to improve management and survival

References

• Grogan M, Dispenzieri A, Gertz MA. Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response. Heart. 2017;103(14):1065–1072.
   PubMed Web of Science ®Google Scholar
• Damy T, Kristen AV, Suhr OB, et al. Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS). Eur Heart J. 2019:ehz173. doi:https://doi.org/10.1093/eurheartj/ehz173
   Google Scholar
• Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404–2412.
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009;120(13):1203–1212.
   PubMed Web of Science ®Google Scholar
• Escher F, Senoner M, Doerler J, et al. When and how do patients with cardiac amyloidosis die? Clin Res Cardiol. 2020;109(1):78–88.
   PubMed Web of Science ®Google Scholar
• Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012;126(10):1286–1300.
   PubMed Web of Science ®Google Scholar
• Sperry BW, Vranian MN, Hachamovitch R, et al. Subtype-specific interactions and prognosis in cardiac amyloidosis. J Am Heart Assoc. 2016;5(3):e002877.
   PubMed Web of Science ®Google Scholar
• Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387(10038):2641–2654.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol. 2015;66(21):2451–2466.
   PubMed Web of Science ®Google Scholar
• Algalarrondo V, Antonini T, Theaudin M, et al. Cause of death analysis and temporal trends in survival after liver transplantation for transthyretin familial amyloid polyneuropathy. Amyloid. 2018;25(4):253–260.
   PubMed Web of Science ®Google Scholar
• Gillmore JD, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39(30):2799–2806.
   PubMed Web of Science ®Google Scholar
• Béquignon E, Guellich A, Bartier S, et al. How your ears can tell what is hidden in your heart: wild-type transthyretin amyloidosis as potential cause of sensorineural hearing loss in elderly-AmyloDEAFNESS pilot study. Amyloid. 2017;24(2):96–100.
   PubMed Web of Science ®Google Scholar
• Zile MR, I-Preserve Investigators, Gaasch WH, Anand IS, et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in heart failure with preserved ejection fraction study (I-Preserve) trial. Circulation. 2010;121(12):1393–1405.
   PubMed Web of Science ®Google Scholar
• Hamaguchi S, JCARE-CARD Investigators, Kinugawa S, Sobirin MA, et al. Mode of death in patients with heart failure and reduced vs. preserved ejection fraction: report from the registry of hospitalized heart failure patients. Circ J. 2012;76(7):1662–1669.
   PubMed Web of Science ®Google Scholar
• Vaduganathan M, Patel RB, Michel A, et al. Mode of death in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2017;69(5):556–569.
   PubMed Web of Science ®Google Scholar
• O'Connor CM, Carson PE, Miller AB, et al. Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. Prospective randomized amlodipine survival evaluation. Am J Cardiol. 1998;82(7):881–887.
   PubMedGoogle Scholar
• Group M-HS. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999;353(9169):2001–2007.
   PubMed Web of Science ®Google Scholar
• Desai AS, for the EVALUATE-HF Investigators, Solomon SD, Shah AM, et al. Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2019;322(11):1077–1010.
   PubMed Web of Science ®Google Scholar
• Oghina S, Bougouin W, Bézard M, et al. The impact of patients with cardiac amyloidosis in HFpEF trials. JACC Heart Fail. 2021;9(3):169–178.
   PubMedGoogle Scholar
• Desai AS, McMurray JJ, Packer M, et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J. 2015;36(30):1990–1997.
   PubMed Web of Science ®Google Scholar
• González-López E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585–2594.
   PubMed Web of Science ®Google Scholar
• Bennani Smires Y, Victor G, Ribes D, et al. Pilot study for left ventricular imaging phenotype of patients over 65 years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy. Int J Cardiovasc Imaging. 2016;32(9):1403–1413.
   PubMed Web of Science ®Google Scholar
• D'Errico S, Mazzanti A, Baldari B, et al. Sudden death in lambda light chain AL cardiac amyloidosis: a review of literature and update for clinicians and pathologists. Int J Clin Exp Pathol. 2020;13(7):1474–1482.
   PubMed Web of Science ®Google Scholar
• Sattar Y, Ruiz Maya T, Zafrullah F, et al. Diagnosis and management of a cardiac amyloidosis case mimicking hypertrophic cardiomyopathy. Cureus. 2018;10(12):e3749.
   PubMed Web of Science ®Google Scholar
• Grupper A, Park SJ, Pereira NL, et al. Role of ventricular assist therapy for patients with heart failure and restrictive physiology: improving outcomes for a lethal disease. J Heart Lung Transplant. 2015;34(8):1042–1049.
   PubMed Web of Science ®Google Scholar
• Mehra MR, International Society for Heart Lung Transplantation (ISHLT) Infectious Diseases, Pediatric and Heart Failure and Transplantation Councils, Canter CE, Hannan MM, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update. J Heart Lung Transplant. 2016;35(1):1–23.
   PubMed Web of Science ®Google Scholar
• Bézard M, Kharoubi M, Galat A, et al. Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis. Eur J Heart Fail. 2021;23(2):264–274.
   PubMed Web of Science ®Google Scholar
• Bézard M, Oghina S, Vitiello D, et al. Dexamethasone is associated with early deaths in light chain amyloidosis patients with severe cardiac involvement. PLoS One. 2021;16(9):e0257189.
   PubMed Web of Science ®Google Scholar
• Le Bras F, Molinier-Frenkel V, Guellich A, et al. Sequential cyclophosphamide-bortezomib-dexamethasone unmasks the harmful cardiac effect of dexamethasone in primary light-chain cardiac amyloidosis. Eur J Cancer. 2017;76:183–187.
   PubMed Web of Science ®Google Scholar
• Sayed RH, Rogers D, Khan F, et al. A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis. Eur Heart J. 2015;36(18):1098–1105.
   PubMed Web of Science ®Google Scholar
• Rehorn MR, Loungani RS, Black-Maier E, et al. Cardiac implantable electronic devices: a window into the evolution of conduction disease in cardiac amyloidosis. JACC Clin Electrophysiol. 2020;6(9):1144–1154.
   PubMedGoogle Scholar
• Hamon D, Algalarrondo V, Gandjbakhch E, et al. Outcome and incidence of appropriate implantable cardioverter-defibrillator therapy in patients with cardiac amyloidosis. Int J Cardiol. 2016;222:562–568.
   PubMed Web of Science ®Google Scholar
• Vardeny O, Solomon SD. Influenza vaccination: a one-shot deal to reduce cardiovascular events. Eur Heart J. 2017;38(5):334–337.
   PubMed Web of Science ®Google Scholar
• Corrales-Medina VF, Alvarez KN, Weissfeld LA, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA. 2015;313(3):264–274.
   PubMed Web of Science ®Google Scholar
• Musher DM, Rueda AM, Kaka AS, et al. The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis. 2007;45(2):158–165.
   PubMed Web of Science ®Google Scholar
• Marra F, Zhang A, Gillman E, et al. The protective effect of pneumococcal vaccination on cardiovascular disease in adults: a systematic review and meta-analysis. Int J Infect Dis. 2020;99:204–213.
   PubMed Web of Science ®Google Scholar
• Sandek A, Bauditz J, Swidsinski A, et al. Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol. 2007;50(16):1561–1569.
   PubMed Web of Science ®Google Scholar
• Niebauer J, Volk HD, Kemp M, et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet. 1999;353(9167):1838–1842.
   PubMed Web of Science ®Google Scholar
• Fukui H. Increased intestinal permeability and decreased barrier function: does it really influence the risk of inflammation? Inflamm Intest Dis. 2016;1(3):135–145.
   PubMedGoogle Scholar